SequelSEC

Imunon, Inc. IMNN

Pharmaceutical Preparations · CIK 0000749647 · Fiscal year ends 1231

Revenue
$500.00K
Fiscal year ended 2022-12-31
Operating income
-$24.92M
Fiscal year ended 2022-12-31
Free cash flow
-$23.36M
Fiscal year ended 2022-12-31

Imunon, Inc. (IMNN) reported revenue of $500.00K and net income of -$35.90M for the fiscal year ended 2022-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Imunon, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Imunon, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenue$500.00K$500.00K$500.00K$500.00K$500.00K$500.00K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$24.92M-$21.01M-$18.49M-$20.57M-$21.07M-$18.47M
Net income-$35.90M-$20.77M-$21.48M-$16.85M-$11.88M-$20.40M
Research & development$11.73M$10.62M$11.34M$13.07M$11.87M$13.08M
Weighted-average diluted sharesshares 7.14MUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$37.47M-$22.15M-$23.33M-$18.67M-$22.30M-$20.40M
Income tax expense-$1.57M-$1.38M-$1.85M-$1.82M-$10.42MUnavailable
Diluted EPS$-5.03UnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$13.69M$10.89M$7.64M$8.00M$9.70M$5.89M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Imunon, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Cash & equivalents$11.49M$19.59M$17.16M$6.88M$13.35M$11.44M
Total assets$43.98M$74.05M$37.53M$38.28M$46.86M$47.51M
Current assets$36.78M$51.95M$18.82M$16.24M$28.13M$24.31M
Total liabilities$14.65M$18.25M$18.92M$23.72M$25.99M$20.81M
Current liabilities$10.04M$6.77M$6.75M$7.89M$6.11M$6.20M
Total equity incl. NCI$29.33M$55.80M$18.61M$14.56M$20.86M$26.70M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$0Unavailable$0UnavailableUnavailableUnavailable
GoodwillUnavailableUnavailable$1.98M$1.98M$1.98M$1.98M
Long-term debt$5.96MUnavailable$5.05M$9.80M$9.42MUnavailable
Accounts payable$3.59M$2.55M$2.24M$2.86M$3.02M$3.42M

Cash flow

Imunon, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Operating cash flow-$23.10M-$16.22M-$15.62M-$20.26M-$7.04M-$16.64M
Capital expenditures$267.80K$311.61K$19.09K$349.16K$138.40K$38.63K
Investing cash flow$8.28M-$30.12M$7.92M$5.94M-$1.63M-$10.99M
Financing cash flow$6.72M$54.77M$17.98M$7.84M$10.58M$36.45M
Net change in cash-$8.09M$8.42M$10.29M-$6.48M$1.91M$8.82M
Stock-based compensation$2.67M$3.76M$1.85M$2.29M$4.60M$1.11M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$197.00K$702.92K$741.52K$721.66K$356.86K$553.01K

Derived

Imunon, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Free cash flow-$23.36M-$16.54M-$15.64M-$20.61M-$7.18M-$16.68M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-4984.3%-4201.4%-3697.3%-4113.1%-4213.0%-3693.7%
FCF margin-4672.9%-3307.0%-3127.6%-4121.6%-1436.0%-3336.1%
SBC / revenue534.6%751.9%370.3%457.3%920.9%221.0%
Current ratio3.66x7.67x2.79x2.06x4.61x3.92x
Revenue YoY growth0.0%0.0%0.0%0.0%0.0%Unavailable
Net margin-7179.6%-4153.8%-4296.7%-3370.3%-2376.7%-4080.4%
R&D / revenue2346.7%2123.9%2269.0%2613.1%2373.1%2615.7%
CapEx / revenue53.6%62.3%3.8%69.8%27.7%7.7%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IMNN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.